Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Novel Drugs for Cardiology/Vascular Diseases under Development

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type

              Companies

              Secarna Pharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma

              Contact the Supplier

              Lead Product(s): Antisense oligonucleotide therapies

              Therapeutic Area: Cardiology/Vascular Diseases

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Lipigon

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition March 23, 2020

              Details:

              Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

              Ncardia

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of ...

              Contact the Supplier

              Lead Product(s): Cardiomyocytes

              Therapeutic Area: Cardiology/Vascular Diseases

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: BlueRock Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 21, 2020

              Details:

              Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.

              PharmaCompass__DigitalAd